We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cumberland Pharmaceutical Inc | NASDAQ:CPIX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.01 | 0.64% | 1.58 | 1.59 | 1.73 | 1.58 | 1.58 | 1.58 | 48 | 15:31:01 |
*
|
The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
|
|
|
|
CUSIP No. 230770109
|
|
|
|
|
|
|
|
|
|
1
|
|
NAMES OF REPORTING PERSONS.
A.J. Kazimi
|
||||
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) Not applicable
(a)
o
(b)
o
|
||||
3
|
|
SEC USE ONLY
|
||||
4
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
||||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH:
|
|
5
|
|
SOLE VOTING POWER
5,830,270
|
||
|
6
|
|
SHARED VOTING POWER
None
|
|||
|
7
|
|
SOLE DISPOSITIVE POWER
5,830,270
|
|||
|
8
|
|
SHARED DISPOSITIVE POWER
None
|
|||
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
5,830,270
|
||||
10
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
Not applicable
o
|
||||
11
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
36.2%
|
||||
12
|
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IN
|
|
(a)
|
Name of Issuer
|
|
|
Cumberland Pharmaceuticals Inc.
|
|
(b)
|
Address of Issuer's Principal Executive Offices
|
|
|
2525 West End Avenue, Suite 950, Nashville, TN 37203
|
|
(a)
|
Name of Person Filing
|
|
|
A.J. Kazimi
|
|
(b)
|
Address of Principal Business Office or, if none, Residence
|
|
|
2525 West End Avenue, Suite 950, Nashville, TN 37203
|
|
(c)
|
Citizenship
|
|
|
United States
|
|
(d)
|
Title of Class of Securities
|
|
|
Common Stock
|
|
(e)
|
CUSIP Number
|
|
|
230770109
|
|
(a)
|
Amount beneficially owned:
|
|
|
5,830,270
|
|
(b)
|
Percent of class:
|
|
|
36.2%
|
|
(c)
|
Number of shares as to which the person has:
|
|
(i)
|
Sole power to vote or to direct the vote
|
|
|
5,830,270
|
|
(ii)
|
Shared power to vote or to direct the vote
|
|
|
None.
|
|
(iii)
|
Sole power to dispose or to direct the disposition of
|
|
|
5,830,270
|
|
(iv)
|
Shared power to dispose or to direct the disposition of
|
|
|
None.
|
|
February 9, 2018
|
|
Date
|
|
|
|
/s/ A.J. Kazimi*
|
|
Signature
|
|
|
|
A.J. Kazimi, Chairman and Chief Executive Officer
|
|
Name/Title
|
1 Year Cumberland Pharmaceutical Chart |
1 Month Cumberland Pharmaceutical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions